An activatable small-molecule fluorogenic probe for detection and quantification of beta-amyloid aggregates
作者:Meng Zhao、Gang Zhang、Shan Huang、Jingmiao Zhang、Yingzhong Zhu、Xiaxia Zhu、Ruilong Zhang、Fei Li
DOI:10.1016/j.saa.2023.123145
日期:2023.12
(Aβ) peptides in the brain is thought to be a pathological hallmark and initial event before the symptom starts of Alzheimer’s patients. Herein, we developed two series of benzo[d]thiazole-based small-molecule compounds (BM1-BM4, BPM1-BPM4) with a donor–acceptor (D-A) or donor-π-acceptor (D-π-A) architecture, respectively, based on structure–activity relationship. Among them, the optimized BPM1 not only
大脑中β淀粉样蛋白(Aβ)肽在细胞外的积累被认为是阿尔茨海默病患者症状出现之前的病理标志和初始事件。在此,我们开发了两个系列的苯并[ d ]噻唑基小分子化合物(BM1-BM4,BPM1-BPM4),具有供体-受体(DA)或供体-π-受体(D-π-A)结构,分别基于结构-活性关系。其中,优化后的BPM1不仅比其他蛋白质或Aβ单体表现出对Aβ聚集体的最高结合亲和力,而且很容易激活其荧光,荧光增强10倍,从而可以特异性、灵敏地检测Aβ聚集体。BPM1还表现出其他一些优点,包括低分子量、低细胞毒性和优异的生物稳定性。此外,细胞染色结果证实,当用 BPM1 结合的 Aβ 1-42聚集体处理时,SK-N-BE(2) 细胞可以被荧光照亮,并且细胞通透性和损伤也增加。